AAV gene therapy vectors in the TMJ

Sabine M. Brouxhon, Michael Kerry O'Banion, Stephanos Kyrkanides

Research output: Contribution to journalArticlepeer-review

1 Scopus citations


Objectives: The goal of this project was to evaluate the use of two adeno-associated viral vector serotypes, adeno-associated viral vectors (AAV)-2 and AAV-6, approved for and used for gene therapy in humans, for the delivery of therapeutic genes to the temporomandibular joint (TMJ) and the attendant sensory nerves. Methods: Young adult wild-type C57BL/6 mice were intra-articularly inoculated with AAV-2 and AAV-6 encoding the reporter gene gfp, the expression of which was assessed in the TMJ as well as along nerves innervating the TMJ. Results: AAV-2 and AAV-6 serotypes were characterized by varying levels of tissue tropism demonstrating different efficacy of infection for articular chondrocytes, meniscal fibroblasts, and trigeminal neurons. Specifically, AAV-2 infected both neurons and articular chondrocytes/meniscal fibroblasts, whereas AAV-6 showed selectivity primarily for neurons. Conclusions: The results of this study are clinically significant in the successful application of gene therapy vectors for TMJ disorders, as this new knowledge will allow for appropriate targeting of specific therapeutic genes to selective tissues (neurons vs. chondrocytes/fibroblasts) as needed by using specific viral vector serotypes.

Original languageEnglish
Pages (from-to)1561-1566
Number of pages6
JournalClinical and Experimental Dental Research
Issue number6
StatePublished - Dec 2022

Bibliographical note

Publisher Copyright:
© 2022 The Authors. Clinical and Experimental Dental Research published by John Wiley & Sons Ltd.


  • TMJ
  • gene therapy
  • trigeminal nerve
  • vectors

ASJC Scopus subject areas

  • General Dentistry


Dive into the research topics of 'AAV gene therapy vectors in the TMJ'. Together they form a unique fingerprint.

Cite this